-+ 0.00%
-+ 0.00%
-+ 0.00%
Dolby Laboratories posts better-than-expected sales in Q3 CY2026 but full-year sales guidance misses expectations significantly
Share
Listen to the news

DLB Cover Image

Audio and video technology company Dolby Laboratories (NYSE:DLB) announced better-than-expected revenue in calendar Q3 2026 [fiscal Q4 2026], with revenue rising 21.7% year on year to $373.5 million. On the other hand, next quarter’s revenue guidance of $295 million was less impressive, coming in 18% below analysts’ consensus estimates. Its non-GAAP profit of $1.25 per share was 4.6% above analysts’ consensus estimates.

For more on Dolby Laboratories, read our full research report for free.

Dolby Laboratories Q3 CY2026 highlights:

  • Revenue $373.5 million vs S&P analyst consensus of $371.3 million (21.7% year-on-year growth, 0.6% beat)
  • Adjusted EPS $1.25 vs S&P analyst consensus of $1.20 (4.6% beat)
  • Revenue guidance $295 million at the midpoint for Q4 CY2026, below analysts’ consensus estimates of $359.7 million
  • Adjusted EPS guidance $4.35 at the midpoint for fiscal 2027, missing analysts’ consensus estimates by 5.1%
  • Operating margin 25.3%, up from 9.7% in the same quarter last year
  • Market capitalization $5.73 billion

"We delivered a strong fourth quarter and an overall solid finish to the year," said Marc Whitten, President and CEO, Dolby Laboratories. "I joined Dolby this August, inspired by our six decades of success as an industry pioneer and global leader. Dolby has a highly resilient and valuable licensing franchise, deep technology, exceptional partner relationships and a very strong balance sheet. Our priorities are to unlock the full potential of Dolby and our leadership position in media by fostering a high performance culture, simplifying how we do business, leading in the AI era, and driving durable and profitable growth."

Revenue growth

Reviewing a company’s long-term revenue performance reveals insights into its quality. Any business can report a good quarter or two, but the best consistently grow over the long term. Over the last five years, Dolby Laboratories grew its revenue at a weak 2.1% compounded annual growth rate, falling short of our standards.

Dolby Laboratories quarterly revenue

Long-term growth is the most important, but within software, a half-decade historical view may miss new innovations or demand cycles. Dolby Laboratories’s annualized revenue growth of 5.6% over the last two years is above its five-year trend, a positive sign. Dolby Laboratories year-on-year revenue growth

This quarter, Dolby Laboratories reported strong year-on-year revenue growth of 21.7%, and its $373.5 million of revenue topped Wall Street’s consensus estimates by 0.6%. Management is guiding for a 14.9% year-on-year decline in revenue next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 3.8% over the next 12 months, according to S&P, a slight deceleration versus the last two years. This projection is underwhelming and implies its products and services will see some demand headwinds.

Customer acquisition efficiency

The customer acquisition cost, or CAC, payback period represents the months required to recover the cost of acquiring a new customer. Essentially, it’s the break-even point for sales and marketing investments. A shorter CAC payback period is ideal, as it implies better returns on investment and business scalability.

Dolby Laboratories is efficient at acquiring new customers, and its CAC payback period was 19 months this quarter. The company’s rapid recovery of its customer acquisition costs means it can attempt to spur growth by increasing its sales and marketing investments.

Key takeaways from Dolby Laboratories’s Q3 results

Dolby’s outlook offered little encouragement, with next year’s revenue guidance pointing to a significant slowdown in demand and its full-year revenue forecast falling short of Wall Street’s consensus estimates. It was a softer quarter with few positives. Shares fell 2.3% to $57.36 immediately after the results.

Dolby Laboratories’s latest earnings report disappointed. One quarter doesn’t define a company’s quality. To assess whether the stock is a buy at the current price, consider the bigger picture of valuation and business quality alongside the latest earnings. For more on Dolby Laboratories, read our full research report here (it’s free).

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending